Evidence map›Paper›PMID 34689425›Full record

ArticleTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy2022

Ultrastructural observation of filtration membrane in cell-free and concentrated ascites reinfusion therapy for malignant ascites.

Kenichi Koga, Takeshi Ishihara, Yohei Doi, Ryota Suzuki, Masakazu Komatsu, Kosei Abe, Takahiro Tanaka, Ryuji Iwaki, Hiroyuki Hashi, Akira Sugawara

Open access · hybridAbstract read
In one paragraph

Article in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Cell-Free and Concentrated Ascites Reinfusion Therapy (CART) Shows Enhanced Efficacy in Gynecological Cancer Patients: A Post-Marketing Surveillance Study.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025
    Article
  2. Observational
  3. Article
  4. Ultrastructural observation of filtration membrane in cell-free and concentrated ascites reinfusion therapy for malignant ascites.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Kenichi KogaDepartment of Nephrology, Osaka Red Cross Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0002-3758-6805
Takeshi IshiharaDepartment of Clinical Engineering, Osaka Red Cross Hospital, Osaka, Japan.
Yohei DoiDepartment of Nephrology, Osaka Red Cross Hospital, Osaka, Japan.
Ryota SuzukiBlood Purification Business Division, Asahi Kasei Medical Co., Ltd., Tokyo, Japan.
Masakazu KomatsuBlood Purification Business Division, Asahi Kasei Medical Co., Ltd., Tokyo, Japan.
Kosei AbeDevelopment and Planning Department, Asahi Kasei Medical MT Corp., Oita, Japan.
Takahiro TanakaDevelopment and Planning Department, Asahi Kasei Medical MT Corp., Oita, Japan.
Ryuji IwakiDepartment of Palliative Care, Osaka Red Cross Hospital, Osaka, Japan.
Hiroyuki HashiDepartment of Palliative Care, Osaka Red Cross Hospital, Osaka, Japan.
Akira SugawaraDepartment of Nephrology, Osaka Red Cross Hospital, Osaka, Japan.
Osaka Red Cross Hospital · JPAsahi Kasei (Germany) · DEAsahi Kasei (Japan) · JP

Funding

Asahi Kasei Medical Co., Ltd
6 · The paper itself

Abstract

introductionCell-free and concentrated ascites reinfusion therapy (CART) is used for the treatment of diuretic-resistant ascites. An increase in circuit pressure and clogging of the filtration membrane often occur in CART for malignant ascites.

methodsTo clarify the precise mechanism of filter clogging, we performed an ultrastructural observation study of the filtration membrane after the filtration of malignant ascites.

resultsThe deposition on the filtration membrane was composed of blood cells, fibrin, or both. Cellular deposition was associated with a greater number of blood cells in the original ascites fluid. In contrast, fibrin deposition was associated with higher levels of interleukin-6, α1-antitrypsin, haptoglobin, and fibrinogen/fibrin degradation products.

conclusionOur results suggest that the specific pathophysiologies of malignancy (such as inflammation or coagulation/fibrinolysis) and characteristics of malignant ascites (highly concentrated and cell-rich) are associated with clogging of the filtration membrane during CART.

Indexed as

AscitesPeritoneal NeoplasmsAscitic FluidFibrinFiltrationHumansTreatment OutcomeFibrinascitescancerfiltrationmembranesscanning electron microscopy

Identifiers

PMID34689425
PMCPMC9297898
OpenAlexW3209148996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.